Suspicion of sarcopenia as a predictor of toxicity in older people with cancer
Main Article Content
Keywords
Geriatric Assessment, Systemic Therapy, Neoadjuvant, Drug-Related Side Effects and Adverse Reactions
Abstract
Abstract
Background: Functional status is considered the standard criterion prior to systemic therapy administration; however, in older adults with cancer, this criterion may lead to challenges in this group.
Objective: To evaluate the association between suspicion of sarcopenia and systemic treatment toxicity in older adults with cancer.
Material and methods: Prospective cohort study which included 150 older adults with recent diagnosis of cancer, candidates to systemic cancer treatment and who signed informed consent. Older adults with brain metastasis were excluded. Prior to systemic treatment, functional status variables were evaluated: skeletal muscle strength, sarcopenia screening, frailty, and chair stand test. Follow-up evaluations were performed before each systemic treatment cycle. Endpoint was considered as the clinical evidence or laboratory toxicity grade 3 or higher, using the Common Terminology Criteria for Adverse Events, version 5.0, or the completion of the treatment regimen.
Results: The incidence of systemic toxicity was 42.7%. In the comparison between patients without toxicity vs. patients with toxicity, the latter group showed a higher frequency of tobacco use, frailty, risk of sarcopenia, and lower grip strength. Only sarcopenia screening predicted systemic toxicity (hazard ratio [HR]: 2.13, 95% confidence interval [95% CI] 1.16-3.91).
Conclusions: The suspicion of sarcopenia was the only toxicity predictor for systemic therapy in older adults with cancer.
References
1. World Health Organization. Cancer. Geneva: World Health Organization; 2025. Disponible en: https://www.who.int/news-room/fact-sheets/detail/cancer
2. Instituto Nacional de Estadística y Geografía. Estadísticas de Defunciones Registradas. Aguascalientes: INEGI; 2024.
3. Goede V. Frailty and Cancer: Current Perspectives on Assessment and Monitoring. Clin Interv Aging. 2023;18:505-521. doi: 10.2147/CIA.S365494
4. Petermann-Rocha F, Balntzi V, Gray SR, et al. Global prevalence of sarcopenia and severe sarcopenia: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2022;13(1):86-99. doi: 10.1002/jcsm.12783
5. Runzer-Colmenares FM, Urrunaga-Pastor D, Roca-Moscoso MA, et al. Frailty and Vulnerability as Predictors of Chemotherapy Toxicity in Older Adults: A Longitudinal Study in Peru. J Nutr Health Aging. 2020;24(9):966-72.
6. Nishijima TF, Deal AM, Williams GR, et al. Impact of the Cancer and Aging Research Group score and treatment intensity on survival and toxicity outcomes in older adults with advanced noncolorectal gastrointestinal cancers. Cancer. 2022;128(10):1929-36.
7. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649-55
8. Parra-Rodríguez L, Szlejf C, García-González AI, et al. Cross-Cultural Adaptation and Validation of the Spanish-Language Version of the SARC-F to Assess Sarcopenia in Mexican Community-Dwelling Older Adults. Journal of the American Medical Directors Association. 2016;17(12):1142-6.
9. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP 2), and the Extended Group for EWGSOP 2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31.
10. Kim YJ, Bae SU, Kim KE, et al. Effects of the Strength, Assistance in walking, Rise from a chair, Climb stairs, and Falls score on postoperative clinical outcomes following colorectal cancer surgery: a retrospective study. Eur J Clin Nutr. 2025;79(4):358-64. doi: 10.1038/s41430-024-01509-6
11. Martin P, Botsen D, Brugel M, et al. Association of Low Handgrip Strength with Chemotherapy Toxicity in Digestive Cancer Patients: A Comprehensive Observational Cohort Study (FIGHTDIGOTOX). Nutrients. 2022;14(21):4448.
12. Bruijnen CP, Koldenhof JJ, Verheijden RJ, et al. Frailty and checkpoint inhibitor toxicity in older patients with melanoma. Cancer. 2022;128(14):2746-52.
13. Almouaalamy N, Adem SH, Alsubhi AA, et al. Sarcopenia and associated risk factors in oncology outpatients in specialized cancer centers in Saudi Arabia: a cross-sectional study. Ann Med Surg (Lond). 2023;85(6):2592-7. doi: 10.1097/MS9.0000000000000794
14. Sedrak MS, Freedman RA, Cohen HJ, et al.; Cancer and Aging Research Group (CARG). Older adult participation in cancer clinical trials: A systematic review of barriers and interventions. CA Cancer J Clin. 2021;71(1):78-92. doi: 10.3322/caac.21638
15. NORMA Oficial Mexicana NOM-031-SSA3-2012, Asistencia social. Prestación de servicios de asistencia social a adultos y adultos mayores en situación de riesgo y vulnerabilidad. México: Diario Oficial de la Federación; 13 de septiembre de 2012. Disponible en: https://dof.gob.mx/nota_detalle.php?codigo=5267965&fecha=13/09/2012
16. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. Journal of Chronic Diseases. 1987;40(5):373-83.
17. BMI Classification. Global Database on Body Mass Index. World Health Organization; 2010.
18. Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93-9.
19. National Comprehensive Cancer Network. Treatment by cancer type. Plymouth, PA: National Comprehensive Cancer Network; [sin fecha de publicación]. Disponible en: https://www.nccn.org/guidelines/category_1
20. European Society for Medical Oncology. Clinical Practice Guidelines. Geneva: ESMO; 2026. Disponible en: https://www.esmo.org/guidelines
21. American Society of Clinical Oncology. Guidelines, tools, & resources. Alexandria, VA: ASCO. Disponible en: https://society.asco.org/practice-patients/guidelines
22. Fried LP, Tangen CM, Walston J, et al.; Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146-56. doi: 10.1093/gerona/56.3.m146
23. Caldwell LS, Chaffin DB, Dukes-Dobos FN, et al. A Proposed Standard Procedure for Static Muscle Strength Testing. American Industrial Hygiene Association Journal. 1974;35(4):201-6.
24. Reuben DB, Laliberte L, Hiris J, et al. Hierarchical Exercise Scale to Measure Function at the Advanced Activities of Daily Living (AADL) Level. Journal of the American Geriatrics Society. 1990;38(8):855-61.
25. Studenski SA, Peters KW, Alley DE, et al. The FNIH Sarcopenia Project: Rationale, Study Description, Conference Recommendations, and Final Estimates. The Journals of Gerontology: Series A. 2014;69(5):547-58.
26. Parra-Rodríguez L, Szlejf C, García-González AI, et al. Cross-Cultural Adaptation and Validation of the Spanish-Language Version of the SARC-F to Assess Sarcopenia in Mexican Community-Dwelling Older Adults. Journal of the American Medical Directors Association. 2016;17(12):1142-6.
27. Pinheiro PA, Carneiro JA, Coqueiro RS, et al. "Chair Stand Test" as Simple Tool for Sarcopenia Screening in Elderly Women. J Nutr Health Aging. 2016;20(1):56-9. doi: 10.1007/s12603-016-0676-3
28. US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. November 27, 2017. Disponible en: https://dctd.cancer.gov/research/ctep-trials/for-sites/adverse-events/ctcae-v5-5x7.pdf
29. Baltussen JC, de Glas NA, van Holstein Y, et al. Chemotherapy-Related Toxic Effects and Quality of Life and Physical Functioning in Older Patients. JAMA Network Open.2023;6(10):e2339116.
30. Luciani A, Biganzoli L, Colloca G, et al. Estimating the risk of chemotherapy toxicity in older patients with cancer: The role of the Vulnerable Elders Survey-13 (VES-13). Journal of Geriatric Oncology. 2015 Jul;6(4):272-9.
31. Cohen HJ, Smith D, Sun CL, et al.; Cancer and Aging Research Group. Frailty as determined by a comprehensive geriatric assessment-derived deficit-accumulation index in older patients with cancer who receive chemotherapy. Cancer. 2016;122(24):3865-72. doi: 10.1002/cncr.30269
32. Bergman M, Fountoukidis G, Smith D, et al. Effect of Smoking on Treatment Efficacy and Toxicity in Patients with Cancer: A Systematic Review and Meta-Analysis. Cancers (Basel). 2022;14(17):4117. doi: 10.3390/cancers14174117
33. Pergolotti M, Sattar S. Measuring functional status of older adults with cancer with patient and performance-based measures, a how-to guide: A young society of geriatric oncology and nursing and allied health initiative. J Geriatr Oncol. 2021;12(3):473-8. doi: 10.1016/j.jgo.2020.09.025
34. Retornaz F, Guillem O, Rousseau F, et al. Predicting Chemotherapy Toxicity and Death in Older Adults with Colon Cancer: Results of MOST Study. The Oncologist. 2019 Aug 6;25(1).
35. Piotrowicz K, Głuszewska A, Czesak J, et al. SARC-F as a case-finding tool for sarcopenia according to the EWGSOP2. National validation and comparison with other diagnostic standards. Aging Clin Exp Res. 2021;33(7):1821-1829. doi: 10.1007/s40520-020-01782-y
36. Silva HKM, Cavalcante LS, Almeida GAS, et al. "Risk of Sarcopenia and Gastrointestinal Toxicity of Older Patients Undergoing Chemotherapy. Revista Brasileira de Cancerologia. 2025: e-054606.
37. Siqueira JM, de Oliveira ICL, Soares JDP, et al. SARC-F has low correlation and reliability with skeletal muscle mass index in older gastrointestinal cancer patients. Clin Nutr. 2021 Mar;40(3):890-894. doi: 10.1016/j.clnu.2020.08.018
Article Sidebar
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.